Michael Hambuchen, PharmD, Ph. D.

image of michael
SKH 353
304-696-7297

Biography

Dr. Hambuchen completed his PharmD at the University of Arkansas for Medical Sciences (UAMS) College of Pharmacy in 2007. He received his PhD in pharmacology in 2013 from the UAMS Graduate School. His dissertation research involved the preclinical study of experimental monoclonal antibody and vaccine pharmacotherapies for the treatment of methamphetamine use disorder. He was a pharmacology lecturer at the UAMS College of Pharmacy from 2014 – 2018 and was an instructor in the Pharmacology and Toxicology department at the UAMS College of Medicine from 2015 – 2018. In the instructor position, he worked as a co-investigator on a National Institute of Drug Abuse R01 “Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse.” His role involved the development of chiral quantitation techniques for MDPV and the design and implementation of preclinical MDPV pharmacokinetic and organ disposition studies.

Dr. Hambuchen’s research interests involve the preclinical study of experimental therapeutics for substance use disorders. Specifically, he is interested in testing and developing new pharmacotherapies for these indications and new experimental models to test these pharmacotherapies.
Dr. Hambuchen teaches Therapeutics IV (CNS, PHAR 751)

University of Arkansas for Medical Sciences (UAMS) College of Pharmacy in 2007, PharmD
PhD in pharmacology in 2013 from the UAMS Graduate School
Instructor in the Pharmacology and Toxicology department at the UAMS College of Medicine from 2015 – 2018
Pharmacology lecturer at the UAMS College of Pharmacy from 2014 – 2018
Preclinical study of experimental monoclonal antibody and vaccine pharmacotherapies for the treatment of methamphetamine use disorder
https://www.ncbi.nlm.nih.gov/sites/myncbi/michael.hambuchen.1/bibliography/52957504/public/?sort=date&direction=ascending
worked as a co-investigator on a National Institute of Drug Abuse R01 “Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse.”
involved the development of chiral quantitation techniques for MDPV and the design and implementation of preclinical MDPV pharmacokinetic and organ disposition studies